Articles by Louise M. Perkins, Ph.D., MRA Chief Science Officer


‘Practice Changing’ Results Hint at New Adjuvant Therapy Treatment Options

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 30 September 2017 In Treatment

Adjuvant treatment is used in addition to tumor removal e.g. via surgery or radiotherapy to help delay or prevent the recurrence of melanoma. It is often recommended for high-risk melanoma (defined as melanoma deeper or thicker than 4mm thick at the primary site or involves nearby lymph nodes). Approved adjuvant therapies in melanoma include interferon and, more recently, ipilimumab. But neither of these approaches is wholly satisfying since relatively few patients appear to benefit and side-effects are a major factor.

Read More


Melanoma Treatments: Breakthroughs for Multiple Cancers — for Real and Right Now

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 10 July 2017 In Science, Treatment

While 2014 and 2015 offered a whirlwind of good news related to new melanoma treatments from immune to targeted therapy, since then, it’s been a bit quieter in melanoma. Although there has been exceptional news in regard to other cancers. Why is that, and what are the latest breakthroughs?

Read More


Spotlight on MRA’s Ninth Annual Scientific Retreat

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 28 February 2017 In Allies & Partnerships, Events, Science

In mid-February, MRA held its premiere research event — the 9th Annual Scientific Retreat, in Washington, DC. A total of 297 individuals registered for the meeting representing a spectrum of key stakeholders in melanoma including academic investigators, pharmaceutical and biotech company representatives, melanoma advocates from various different non-profit organizations, donors and government officials.

Read More


Melanoma 2016 — the Year in Review

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 20 January 2017 In News

In the nearly 10 years since MRA’s founding in 2007, there has been extraordinary progress for melanoma. With 11 new treatments approved since 2011, it began to feel like frequent new drug approvals was the current norm.

Read More


Uncommon Immunotherapy Side Effects

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 30 November 2016

A recent report in the prestigious New England Journal of Medicine (NEJM), has spawned reports like this one, regarding the risk of death in patients treated with combination checkpoint treatments. The first author of the NEJM story is MRA-funded investigator, Doug Johnson at Vanderbilt.

Read More


Championing Collaboration

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 30 November 2016

Some have the impression that cancer researchers, whether in academia or in industry, toil away in isolation. While there are certainly scientists who work best on their own, collaboration among researchers has become increasingly common, with a goal of achieving the most promising results in the shortest time frame.

Read More


To Screen or Not to Screen (for Skin Cancer) – Reframing the Question

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 29 July 2016

To screen or not to screen actually isn’t the question  While an adaptation of Hamlet’s famous phrase may capture the headlines on whole-body skin checks, a deeper dive gets us closer to questions of life and death.

Read More


Highlights from the National Cancer Moonshot Summit

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 7 July 2016 In Events, News

The National Cancer Moonshot was announced by President Obama in his State of the Union Address in January 2016 and VP Biden was charged with spearheading the effort. Few would disagree with Mr. Biden’s selection as leader given the personal experience he and his family endured with the loss of...

Read More


Whither melanoma and whither cancer research? 

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 10 May 2016 In Events, Prevention, Science, Treatment

There is no doubt that the last few years have seen incredible progress for melanoma patients with 11 treatments approved since MRA’s founding in 2007: personalized medicine, targeted therapy, immunotherapy. What remains to be done for melanoma and other cancers? How are the successes in melanoma and other research areas...

Read More


Fast and Furious: Melanoma Research in 2015

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 28 December 2015 In Science, Treatment

The world of melanoma has changed dramatically in a way one might not have envisioned in 2011. How can you tell?  From the stories of patients and their caregivers. A common story can go like this: Just diagnosed with Stage 4 melanoma.

Read More


About the Author
Louise M. Perkins, Ph.D., MRA Chief Science Officer


MRA Chief Science Officer

Login

×